Contraception is more commonly known as fertility and birth control which are described as the methods to avoid pregnancy. These devices and drugs function by changing the mechanism of ovulation or by acting as a physical barrier between the sperm and ovum. The proper use of contraceptives, such as female and male condoms, also prevents the spread of sexually transmitted diseases. There are also behavioral, dual protection and emergency controls available for prevention of pregnancy. The global market for contraceptives encompasses oral, vaginal, and injectable contraceptive drugs and male/female contraceptive devices. These products are readily available at outlets ranging from pharmacies and chemists to reproductive health and fertility centers. Rising number of government initiatives to spread awareness about these drugs and devices is the most significant driver of the global market. Moreover, rising global prevalence of sexually transmitted diseases also serves the market as a driver. The market for contraceptives is also influenced by political and social considerations.
Key product segments analyzed in this study include contraceptive drugs, male contraceptive devices, and female contraceptive devices. The highest demand in the market is for contraceptives drugs. With the advancement in technology and the development of new emergency oral contraceptive pills are seen as the easiest method of contraception. They act by prohibiting implantation within the uterus if taken within 2-3 days of having unsafe sexual contact. The simplicity of their usage makes them an ideal contraceptive in the market. The other forms of contraceptive drugs such as topical and injectable contraceptives also witness strong market demand. The future growth of the contraceptive drugs and devices market will be fuelled by the introduction of cheap contraceptives such as Sino-Implant (II) and the presence of an extensive contraceptives product pipeline (e.g. male contraceptive drugs, Pill-Plus and AG200-15 Contraceptive Patch).
North America, Europe, Asia Pacific, and RoW are the major geographies analyzed in this study. Europe and North America owing to the presence of sophisticated healthcare infrastructure, high adoption rate of contraceptive drugs, and rising number of government initiatives pertaining to elevating user awareness levels dominated the overall market in 2013. However, the presence of high contraception-related unmet medical needs coupled with rising consumer awareness levels and disposable incomes will help the Asia-Pacific contraceptive drugs and devices market to register the highest growth rate during the forecast period. The healthcare policies introduced in these countries aim at increasing the availability of contraceptive drugs and devices which would curb population increase.
Key players of this market include Bayer Healthcare AG, Merck & Co., Church & Dwight Co. Inc., Warmer Chilcott Company inc., Agile Therapeutics Inc., Pfizer Inc., BioSante Pharmaceuticals, Mayer Laboratories Inc., Pantarhei Bioscience B.V., and Teva Pharmaceutical Industries Ltd.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.
Contact us now to get our best pricing.
ESOMAR certified & member
Leading SME award by D&B
"The quality of research they have done for us has been excellent."
Multiple therapeutic regimens are being followed across the globe in attempts to come up with a reliable treatment for Covid-19. One line of treatment includes the use of hydroxychloroquine, while a second treatment line focuses to use antiviral drugs used in the disease management of HIV. Both these approaches have surged demand from advanced antivirals and antimalarial drugs. This impacts the drug manufacturers as an off label indication for these drug classes has to be worked upon. At the moment, the WHO has not prescribed any of these approaches, neither they have commented if one is better than the other. The report will account for Covid19 as a key market contributor.